Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.

British journal of cancer - 21 Jan 2014

Khatri A, Williams B W, Fisher J, Brundage R C, Gurvich V J, Lis L G, Skubitz K M, Dudek A Z, Greeno E W, Kratzke R A, Lamba J K, Kirstein M N

Abstract excerpt

BACKGROUND: Gemcitabine is used for the treatment of several solid tumours and exhibits high inter-individual pharmacokinetic variability. In this study, we explore possible predictive covariates on drug and metabolite disposition. METHODS: Forty patients were enrolled. Gemcitabine and dFdU concentrations in the plasma and dFdCTP concentrations in peripheral blood mononuclear cell were measured to 72 h post...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 5'-Nucleotidase
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytidine Deaminase

Share to Deoxycytidine

Share to Gemcitabine

Share to Infusions, Intravenous

Share to Leukocytes, Mononuclear

Share to Membrane Transport Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24300978
DOI: 10.1038/bjc.2013.738
PMCID: PMC3899768

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.PMID 24300978Read ↗

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.Semantic proximity Read ↗

Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.Semantic proximity Read ↗

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.Semantic proximity Read ↗

Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.Semantic proximity Read ↗

The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.Semantic proximity Read ↗

Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.Semantic proximity Read ↗

Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.Semantic proximity Read ↗

Clinical pharmacology and pharmacogenetics of gemcitabineSemantic proximity Read ↗

Comprehensive statistical analysis of the pharmacokinetics, safety and clinical benefit rate of MitoTam in a single-center phase I/Ib trial in patients with metastatic solid tumorsSemantic proximity Read ↗

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.Semantic proximity Read ↗

Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.Semantic proximity Read ↗

Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.